ImageneBio is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases with differentiated clinical profiles. The company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
| Website | http://www.imagenebio.com/ |
| Employees | 46 (38 on RocketReach) |
| Founded | 2019 |
| Address | 12526 High Bluff Drive Suite 345, San Diego, California 92130, US |
| Industry | Biotechnology Research |
Looking for a particular ImageneBio employee's phone or email?
Kristin Yarema is the CEO of ImageneBio.
38 people are employed at ImageneBio.
ImageneBio is based in San Diego, California.